@article{79a11977d313429caa9df37909ccdb06,
title = "Healthcare Costs for Metastatic Breast Cancer Patients Ttreated with Human Epidermal Growth Factor Receptor 2 Targeted Agents",
abstract = " D. Lalla; N. Oestreicher; A. Ogbonnaya; V. Saundankar; J. Willey; A. Coutinho; K. McCann ",
author = "Reshma Mahtani",
note = "Abstract. Background: Human Epidermal Growth Factor Receptor 2 positive (HER2+) breast cancer (BC) represents approximately 15\% of early stage BC cases and is associated with a more aggressive clinical phenotype and poor prognosis with respect to most BC. Over the last decade new HER2-targeted therapies have become available that have prolonged survival for both early stage and metastatic breast cancer (mBC).",
year = "2021",
month = feb,
day = "15",
language = "American English",
volume = "81",
journal = "Cancer Research / San Antonio Breast Cancer Symposium",
}